In vitro efficacy of artemisinin-based treatments against SARS-CoV-2.

A549 Cells Animals Artemisia annua / chemistry Artemisinins / pharmacology Chlorocebus aethiops Humans Plant Extracts / pharmacology SARS-CoV-2 / drug effects Vero Cells COVID-19 Drug Treatment

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 07 2021
Historique:
received: 06 10 2020
accepted: 23 06 2021
entrez: 17 7 2021
pubmed: 18 7 2021
medline: 24 7 2021
Statut: epublish

Résumé

Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed. We report in vitro efficacy of Artemisia annua extracts as well as artemisinin, artesunate, and artemether against SARS-CoV-2. The latter two are approved active pharmaceutical ingredients of anti-malarial drugs. Concentration-response antiviral treatment assays, based on immunostaining of SARS-CoV-2 spike glycoprotein, revealed that treatment with all studied extracts and compounds inhibited SARS-CoV-2 infection of VeroE6 cells, human hepatoma Huh7.5 cells and human lung cancer A549-hACE2 cells, without obvious influence of the cell type on antiviral efficacy. In treatment assays, artesunate proved most potent (range of 50% effective concentrations (EC

Identifiants

DOI: 10.1038/s41598-021-93361-y PMID: 34272426 PMC: PMC8285423
pubmed: 34272426
doi: 10.1038/s41598-021-93361-y
pii: 10.1038/s41598-021-93361-y
pmc: PMC8285423
doi:

Substances chimiques

Artemisinins 0
Plant Extracts 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14571

Informations de copyright

© 2021. The Author(s).

Références

Semin Cancer Biol. 2017 Oct;46:65-83
pubmed: 28254675
Antiviral Res. 2015 Nov;123:105-13
pubmed: 26374952
BMJ. 2020 Oct 19;371:m4057
pubmed: 33077424
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
J Virol. 2006 Mar;80(6):2609-20
pubmed: 16501071
Antiviral Res. 2005 Jul;67(1):18-23
pubmed: 15885816
Gastroenterology. 2011 Mar;140(3):1032-42
pubmed: 21111742
J Virol. 2002 Dec;76(24):13001-14
pubmed: 12438626
JAMA. 2020 Feb 25;323(8):707-708
pubmed: 31971553
Molecules. 2010 Apr 29;15(5):3135-70
pubmed: 20657468
Antimicrob Agents Chemother. 2021 Jun 7;:AAC0268020
pubmed: 34097489
Virus Res. 2006 Dec;122(1-2):119-26
pubmed: 16920216
Phytomedicine. 2017 Aug 15;32:37-40
pubmed: 28732806
ACS Infect Dis. 2020 Sep 11;6(9):2524-2531
pubmed: 32786284
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Gastroenterology. 2011 Sep;141(3):1067-79
pubmed: 21699793
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
J Pharm Biomed Anal. 2008 Nov 4;48(3):876-84
pubmed: 18762400
Anesth Prog. 2007 Spring;54(1):19-23; quiz 24-5
pubmed: 17352523
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0009721
pubmed: 33903110
Science. 1985 May 31;228(4703):1049-55
pubmed: 3887571
Acta Pharmacol Sin. 2009 Jan;30(1):25-30
pubmed: 19060918
Eur J Pharmacol. 2011 Oct 1;668(1-2):6-14
pubmed: 21756901
Lancet. 2012 Dec 1;380(9857):1916-26
pubmed: 23122217
Malar J. 2011 Sep 13;10:263
pubmed: 21914160
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Clin Infect Dis. 2008 Sep 15;47(6):804-11
pubmed: 18699744
J Virol. 2010 May;84(10):5277-93
pubmed: 20200247

Auteurs

Yuyong Zhou (Y)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Kerry Gilmore (K)

Max Planck Institute for Colloids and Interfaces, Am Mühlenberg 1, 14476, Potsdam, Germany.

Santseharay Ramirez (S)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Eva Settels (E)

Max Planck Institute for Colloids and Interfaces, Am Mühlenberg 1, 14476, Potsdam, Germany.

Karen A Gammeltoft (KA)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Long V Pham (LV)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Ulrik Fahnøe (U)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Shan Feng (S)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Anna Offersgaard (A)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Jakob Trimpert (J)

Institute for Virology, Freie Universität Berlin, Robert von Ostertag-Str. 7-13, 14163, Berlin, Germany.

Jens Bukh (J)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.

Klaus Osterrieder (K)

Institute for Virology, Freie Universität Berlin, Robert von Ostertag-Str. 7-13, 14163, Berlin, Germany. no34@cornell.edu.
Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong. no34@cornell.edu.

Judith M Gottwein (JM)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650, Hvidovre, Denmark. jgottwein@sund.ku.dk.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. jgottwein@sund.ku.dk.

Peter H Seeberger (PH)

Max Planck Institute for Colloids and Interfaces, Am Mühlenberg 1, 14476, Potsdam, Germany. peter.seeberger@mpikg.mpg.de.
Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195, Berlin, Germany. peter.seeberger@mpikg.mpg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules A549 › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Eucaryotes › Animaux › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Asteraceae › Artemisia › Artemisia annua › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Sesquiterpènes › Artémisinines › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Cercopithecus › Cercopithecus aethiops › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Préparations pharmaceutiques › Extraits de plantes › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules Vero › In vitro efficacy of artemisinin-based...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitements médicamenteux de la COVID-19 › In vitro efficacy of artemisinin-based...